BrainSightAI Secures $5 Million to Revolutionize Brain Care with AI and Neuroscience

BrainSightAI Secures $5 Million in Pre-Series A Funding

Bengaluru-based neuroscience startup BrainSightAI has successfully raised $5 million in a pre-Series A funding round led by IAN Alpha Fund. The round also saw participation from IvyCap Ventures, Silver Needle, and existing investors 1

1

2

2

3

3

. This significant investment marks a crucial step in the company's mission to revolutionize brain care through the integration of artificial intelligence (AI) and neuroscience.

Innovative AI-Powered Solutions for Brain Disorders

BrainSightAI's product suite includes two groundbreaking solutions:

1. Voxelbox: A platform that provides clinicians with access to a functional magnetic resonance imaging (fMRI) processing engine and machine learning models. This tool aids in generating reports for clinical decision-making, particularly in brain tumor cases 1

   1

   3

   3

   .

2. Snowdrop: A patient care app that enables compliance with treatment schedules and helps build comprehensive patient profiles 1

   1

   2

   2

   .

These AI-powered tools aim to enable precision in neurological and psychiatric investigations, resulting in faster and more accurate patient outcomes.

Expansion Plans and FDA Certification

With the new funding, BrainSightAI plans to:

1. Expand its presence across major Indian cities and extend into tier 2 markets 1

   1

   2

   2

   .
2. Pursue Food and Drug Administration (FDA) certification to access US and allied markets 1

   1

   2

   2

   3

   3

   .
3. Explore opportunities in Africa and Southeast Asia 1

   1

   2

   2

   .
4. Support research and development for a caregiver-focused app to empower families of patients with brain disorders 1

   1

   2

   2

   3

   3

   .

Current Collaborations and Future Prospects

BrainSightAI currently collaborates with over 40 hospitals across India, primarily in neurosurgery and radiology departments 1

1

3

3

. The company is expanding its offerings to address a broader range of neurological and psychiatric disorders 1

1

.

Laina Emmanuel, CEO and co-founder of BrainSightAI, expressed excitement about the potential of connectomics to advance personalized brain care 1

1

2

2

3

3

. The company aims to reach a $100 million annual recurring revenue run rate by scaling across India and expanding globally 1

1

.

Impact on Brain Disorder Diagnosis and Treatment

BrainSightAI's technology combines AI and neuroscience to map neural connections, enabling precise diagnosis and prognosis of neuro-oncological and neuropsychiatric disorders. This advanced technology, previously exclusive to institutions like Harvard and Stanford, is now being made accessible to hospitals and patients worldwide 3

3

.

Priyank Garg, managing partner at IAN Alpha Fund, highlighted the transformative potential of BrainSightAI's connectomics platform, VoxelBox, in revolutionizing the diagnosis and treatment of brain disorders 1

1

.

As BrainSightAI continues to grow and innovate, it stands at the forefront of a new era in personalized brain care, leveraging AI and neuroscience to improve patient outcomes and democratize access to advanced neurological treatments.